Utah Medical ProductsUTMD
UTMD
About: Utah Medical Products Inc is involved in the business of developing, manufacturing, and distributing medical devices that are mainly proprietary, disposable and for hospital use. The firm produces its products for Blood pressure monitoring, Blood collection, Electrosurgery, Gynecology, Neonatal critical care, perinatology, and Urology. The company's product portfolio includes Electrosurgical pens, Tenacula, Endoscopic bulb irrigators, Blood bag spikes. Its products are used mainly in critical care areas, labor and delivery departments of hospitals as well as outpatient clinics and physicians offices.
Employees: 190
0
Funds holding %
of 7,290 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
12% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 17
11% more repeat investments, than reductions
Existing positions increased: 40 | Existing positions reduced: 36
2% more funds holding
Funds holding: 110 [Q3] → 112 (+2) [Q4]
3.45% less ownership
Funds ownership: 71.2% [Q3] → 67.75% (-3.45%) [Q4]
15% less capital invested
Capital invested by funds: $166M [Q3] → $141M (-$24.6M) [Q4]
Research analyst outlook
We haven’t received any recent analyst ratings for UTMD.
Financial journalist opinion
Based on 3 articles about UTMD published over the past 30 days
Neutral
Accesswire
2 weeks ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESS Newswire / February 4, 2025 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.305) per share of common stock payable on April 3, 2025 to stockholders of record at the close of business on March 14, 2025. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Negative
Zacks Investment Research
3 weeks ago
Utah Medical's EPS Declines 27% Y/Y in Q4, Stock Drops 5%
UTMD's Q4 EPS drops 27.4% year over year, and revenues fall 25.8% on weak PendoTECH sales. Revenues are expected to decline further in 2025.
Neutral
Accesswire
3 weeks ago
UTMD Reports Year 2024 and Fourth Quarter Financial Performance
SALT LAKE CITY, UT / ACCESS Newswire / January 28, 2025 / With Revenues 19% lower, Net Income 17% lower and Earnings Per Share (EPS) 13% lower than in 2023, Utah Medical Products, Inc. (NASDAQ:UTMD) concluded a year of contraction. UTMD's stock price declined 27%, more than twice the EPS decline, which allowed the Company an opportunity to repurchase more than 8% of its shares in the open market.
Positive
Seeking Alpha
1 month ago
Utah Medical Products: Favorably Skewed Risk/Reward Profile
UTMD has been punished in 2024 despite high-quality business fundamentals and attractive valuation metrics. UTMD's economic characteristics are strong, with high post-tax margins and returns on capital. Projected earnings of $22mm-$31mm by FY'26E, with a valuation range of $67 to $75 per share.
Neutral
Accesswire
3 months ago
Utah Medical Products, Inc. Appoints Director and Increases Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / November 5, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors has appointed Carrie Leigh to its Board of Directors. Ms. Leigh, who was employed in direct sales positions for UTMD from 2004 to 2016, graduated with a B.S.
Neutral
Zacks Investment Research
3 months ago
Utah Medical Q3 Earnings Decline Y/Y on Lower OEM Sales
UTMD reports a 5.2% EPS decline in Q3 2024, with revenues declining 20% due to reduced OEM and Filshie sales. Cost controls helped stabilize profit margins.
Neutral
Accesswire
3 months ago
UTMD Reports Financial Performance for Third Calendar Quarter and Nine Months 2024
SALT LAKE CITY, UT / ACCESSWIRE / October 29, 2024 / Utah Medical Products, Inc. (NASDAQ:UTMD) reports third quarter (3Q) and first nine months (9M) of calendar year 2024 financial results that were weaker on the top line, but better on the bottom line, compared to its beginning of year projections. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Neutral
Accesswire
6 months ago
Utah Medical Products, Inc. Announces Quarterly Dividend
SALT LAKE CITY, UT / ACCESSWIRE / August 2, 2024 / Utah Medical Products, Inc. (Nasdaq:UTMD) announces that its Board of Directors approved a quarterly cash dividend of thirty cents ($.30) per share of common stock payable on October 4, 2024 to stockholders of record at the close of business on September 20, 2024. This is a 1.7% increase over the dividend declared in the same quarter of the prior year.
Negative
Zacks Investment Research
6 months ago
Utah Medical (UTMD) Q2 EPS Falls Y/Y on Lower Key Customer Sales
Utah Medical (UTMD) reports a 19.2% revenue decline in 2Q24, with EPS down 15.3% due to lower sales to major customers. Despite this, profit margins remained stable.
Neutral
Accesswire
6 months ago
UTMD Reports Financial Performance for Second Calendar Quarter and First Half 2024
SALT LAKE CITY, UT / ACCESSWIRE / July 25, 2024 / As previously projected, Utah Medical Products, Inc. (Nasdaq:UTMD) realized second calendar quarter (2Q) and first half (1H) 2024 financial results which reflect a substantial decline in revenues. Currencies in this release are denoted as $ or USD = U.S. Dollars; AUD = Australia Dollars; £ or GBP = UK Pound Sterling; C$ or CAD = Canadian Dollars; and € or EUR = Euros.
Charts implemented using Lightweight Charts™